Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Raw Materials (2018 - 2025)

Protalix BioTherapeutics (PLX) has 10 years of Raw Materials data on record, last reported at $5.0 million in Q3 2025.

  • For Q3 2025, Raw Materials rose 17.47% year-over-year to $5.0 million; the TTM value through Sep 2025 reached $5.0 million, up 17.47%, while the annual FY2024 figure was $4.5 million, 8.93% up from the prior year.
  • Raw Materials reached $5.0 million in Q3 2025 per PLX's latest filing, up from $4.4 million in the prior quarter.
  • Across five years, Raw Materials topped out at $5.0 million in Q3 2025 and bottomed at $3.0 million in Q2 2021.
  • Average Raw Materials over 5 years is $3.9 million, with a median of $4.2 million recorded in 2023.
  • Peak YoY movement for Raw Materials: decreased 21.94% in 2021, then soared 40.51% in 2023.
  • A 5-year view of Raw Materials shows it stood at $3.2 million in 2021, then rose by 10.8% to $3.5 million in 2022, then increased by 19.04% to $4.2 million in 2023, then increased by 8.93% to $4.5 million in 2024, then increased by 9.54% to $5.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Raw Materials were $5.0 million in Q3 2025, $4.4 million in Q2 2025, and $4.5 million in Q1 2025.